Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Danicopan in PNH Extension Study
NCT03181633Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Jun 2017; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03181633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181633.